{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05983432",
            "orgStudyIdInfo": {
                "id": "BL-B01D1-LUNG-101"
            },
            "organization": {
                "fullName": "SystImmune Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study to Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors",
            "officialTitle": "A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects With Metastatic or Unresectable Non-Small Cell Lung Cancer and Other Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "study-to-evaluate-bl-in-patients-with-metastatic-or-unresectable-non-small-cell-lung-cancer-nsclc-and-other-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "startDateStruct": {
                "date": "2023-08-08",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-03-21",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-07-12",
            "studyFirstSubmitQcDate": "2023-08-01",
            "studyFirstPostDateStruct": {
                "date": "2023-08-09",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-19",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-22",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "SystImmune Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.",
            "detailedDescription": "BL-B01D1-LUNG-101 is a global, multi-center, Phase 1 study to evaluate the safety, tolerability, pharmacokinetics , and initial efficacy of BL-B01D1 in participants with metastatic or unresectable NSCLC and Other Solid Tumors.\n\nThis study will be conducted in two different dosing schedules (Cohort A and Cohort B) and three parts (dose escalation, dose finding and dose expansion). Cohort A will be dosed on Day 1 and Day 8 of a continuous 21-day treatment cycle. Cohort B will be dosed on Day 1 of a continuous 21-day treatment cycle. Each Cohort has different dose groups."
        },
        "conditionsModule": {
            "conditions": [
                "Non Small Cell Lung Cancer",
                "NSCLC",
                "Lung Cancer",
                "Breast Cancer",
                "Esophageal Cancer",
                "SCLC",
                "Small Cell Lung Cancer",
                "NPC",
                "Nasopharyngeal Cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 260,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "BL-B01D1 administered Day 1 and Day 8 per cycle",
                    "type": "EXPERIMENTAL",
                    "description": "BL-B01D1 will be administered on Day 1 and Day 8 by intravenous infusion every 3 weeks",
                    "interventionNames": [
                        "Drug: BL-B01D1"
                    ]
                },
                {
                    "label": "BL-B01D1 administered Day 1 per cycle",
                    "type": "EXPERIMENTAL",
                    "description": "BL-B01D1 will be administered on Day 1 via by intravenous infusion every 3 weeks",
                    "interventionNames": [
                        "Drug: BL-B01D1"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "BL-B01D1",
                    "description": "The study includes 3 parts: Part 1 Dose escalation. Part 2 Dose Finding non-randomized and Part 3 Dose expansion randomized.",
                    "armGroupLabels": [
                        "BL-B01D1 administered Day 1 and Day 8 per cycle",
                        "BL-B01D1 administered Day 1 per cycle"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Participants with Dose-limiting toxicities",
                    "description": "Measuring the number of patients Dose-limiting toxicities (DLTs). A DLT is defined as any of the following events that are not clearly due to the underlying disease or extraneous causes:\n\nHematological toxicities:\n\n* Grade 4 neutrophil count decreased lasting \\>7 days\n* Grade \u22653 febrile neutropenia\n* Grade \u22653 platelet count decreased with clinically significant hemorrhage.\n\nNon-Hematological toxicities:\n\n* Death\n* Hy's law cases\n* Grade \u22653 non-hematological toxicities,",
                    "timeFrame": "One year"
                },
                {
                    "measure": "Participants with Serious Adverse Events (SAEs) and treatment-emergent adverse events (TEAEs),",
                    "description": "Measuring the number of patients with serious adverse events (SAEs) and treatment-emergent adverse events (TEAEs)",
                    "timeFrame": "One year"
                },
                {
                    "measure": "Participants with abnormal physical examination findings",
                    "description": "Measure the number of participants with abnormal physical examination findings.",
                    "timeFrame": "One year"
                },
                {
                    "measure": "Participants with ability to care for themselves, daily activity, and physical activity",
                    "description": "Measure the change in participants with Eastern Clinical Oncology Group (ECOG) Scale of Performance Status. The scale is 0-4 with 0 being the fully active (best outcome) and 4 being completely disabled (worst outcome)",
                    "timeFrame": "One year"
                },
                {
                    "measure": "Participants with abnormal ECG reading",
                    "description": "Measure the number of participants with abnormal ECG parameters",
                    "timeFrame": "One year"
                },
                {
                    "measure": "Participants with abnormal lab results",
                    "description": "Measure the number of participants with abnormal clinical laboratory values",
                    "timeFrame": "One year"
                },
                {
                    "measure": "To determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and two or more recommended doses and schedules for recommended dose expansion (RDEs) of BL-B01D1 in metastatic NSCLC",
                    "description": "Determine the highest BL-B01D1 dose level at which \u226433% subjects experience a DLT during the DLT evaluation period and highest BL-B01D1 dose administered in the event and MTD cannot be defined.",
                    "timeFrame": "One year"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Cmax of BL-B01D1",
                    "description": "Calculate maximum (peak) observed concentration of BL-B01D1",
                    "timeFrame": "One year"
                },
                {
                    "measure": "Cmax of anti-EGFR\u00d7HER3 antibody",
                    "description": "Calculate maximum (peak) observed concentration of anti-EGFR\u00d7HER3 antibody",
                    "timeFrame": "One year"
                },
                {
                    "measure": "Cmax of free payload ED-04",
                    "description": "Calculate maximum (peak) observed concentration of free payload ED-04",
                    "timeFrame": "One year"
                },
                {
                    "measure": "Tmax of BL-B01D1",
                    "description": "Calculate time of maximum observed concentration of BL-B01D1",
                    "timeFrame": "One year"
                },
                {
                    "measure": "Tmax of anti-EGFR\u00d7HER3 antibody",
                    "description": "Calculate time of maximum observed concentration of anti-EGFR\u00d7HER3 antibody",
                    "timeFrame": "One year"
                },
                {
                    "measure": "Tmax of free payload ED-04",
                    "description": "Calculate time of maximum observed concentration of free payload ED-04",
                    "timeFrame": "One year"
                },
                {
                    "measure": "AUC(0-8) of BL-B01D1",
                    "description": "Calculate area under the serum concentration-time curve of BL-B01D1 from time 0 to 8 hours",
                    "timeFrame": "One year"
                },
                {
                    "measure": "AUC(0-8) of anti-EGFR\u00d7HER3 antibodies",
                    "description": "Calculate area under the serum concentration-time curve of anti-EGFR\u00d7HER3 antibodies from time 0 to 8 hours",
                    "timeFrame": "One year"
                },
                {
                    "measure": "AUC(0-8) of free payload ED-04",
                    "description": "Calculate area under the serum concentration-time curve of free payload ED-04 from time 0 to 8 hours",
                    "timeFrame": "One year"
                },
                {
                    "measure": "AUC(last) of BL-B01D1",
                    "description": "Calculate area under the serum concentration-time curve up of BL-B01D1 to the last quantifiable time",
                    "timeFrame": "One year"
                },
                {
                    "measure": "AUC(last) anti-EGFR\u00d7HER3 antibodies",
                    "description": "Calculate area under the serum concentration-time curve up of anti-EGFR\u00d7HER3 antibodies to the last quantifiable time",
                    "timeFrame": "One year"
                },
                {
                    "measure": "AUC(last) of free payload ED-04",
                    "description": "Calculate area under the serum concentration-time curve up of free payload ED-04 to the last quantifiable time",
                    "timeFrame": "One year"
                },
                {
                    "measure": "Overall Response Rate (ORR)",
                    "description": "To assess the clinical efficacy of BL-B01D1 as measured by ORR using RECIST criteria v 1.1",
                    "timeFrame": "One year"
                },
                {
                    "measure": "Disease Control Rate (DCR)",
                    "description": "To assess the clinical efficacy of BL-B01D1 as measured by DCR using RECIST criteria v 1.1",
                    "timeFrame": "One year"
                },
                {
                    "measure": "Time To Response (TTR)",
                    "description": "To assess the clinical efficacy of BL-B01D1 as measured by TTR using RECIST criteria v 1.1",
                    "timeFrame": "One year"
                },
                {
                    "measure": "Progression-Free Survival (PFS),",
                    "description": "To assess the clinical efficacy of BL-B01D1 as measured by PFS using RECIST criteria v 1.1",
                    "timeFrame": "One year"
                },
                {
                    "measure": "Overall Survival (OS).",
                    "description": "To assess the clinical efficacy of BL-B01D1 as measured by OS using RECIST criteria v 1.1",
                    "timeFrame": "One year"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Sign informed consent\n2. Expected survival \\> or = 3months\n3. Has histologically documented, incurable, locally advanced or metastatic epithelial origin malignant cancer, priority to include the following tumor types: Non-Small Cell Lung Cancer, HER2- breast cancer, esophageal cancer, Small Cell Lung Cancer, and Nasopharyngeal Cancer\n4. Agree to provide a tumor sample\n5. Has at least one measurable lesion based on RECIST 1.1\n6. Has an Eastern Cooperative Oncology Group performance status (ECOG PS) 0 to 1\n7. Toxicity of previous antitumor therapy has returned to level \u22641 as defined by NCI-CTCAE V5.0 (except for asymptomatic laboratory abnormalities such as elevated ALP, hyperuricemia, elevated serum or plasma amylase/lipase, and elevated blood glucose; except for toxicity that the investigator determined to have no safety risk, such as alopecia, grade 2 peripheral neurotoxicity, hypothyroidism stabilized by hormone replacement therapy, etc.)\n8. Has no serious cardiac dysfunction, left ventricular ejection fraction \u226550%.\n9. Has adequate organ function before registration\n10. Coagulation function: international normalized ratio (INR) \u22641.5\u00d7ULN, and activated partial thromboplastin time (APTT) \u22641.5 ULN\n11. Urinary protein \u22642+ or \u22641000mg/24 hours\n12. For premenopausal women with childbearing potential, a pregnancy test must be taken within 7 days prior to the start of treatment. Serum or urine pregnancy must be negative and must be non-lactating\n13. Must agree to use adequate barrier contraceptive measures during the treatment and 6 months after the end of treatment for all subjects (regardless of gender)\n\nExclusion Criteria:\n\n1. Chemotherapy, biological therapy, immunotherapy, radical radiotherapy, major surgery, targeted therapy and other anti-tumor therapy within 4 weeks or 5 half-lives (whichever is shorter) prior to the first administration\n2. Subjects with history of severe heart disease\n3. Active autoimmune diseases and inflammatory diseases\n4. Other malignant tumors were diagnosed within 5 years\n5. Subjects with poorly controlled hypertension\n6. Subjects have Grade 3 lung disease or a history of interstitial lung disease\n7. Unstable thrombotic events such as deep vein thrombosis, arterial thrombosis, and pulmonary embolism requiring therapeutic intervention within the previous 6 months before screening\n8. Symptoms of active central nervous system metastasis\n9. Subjects who have a history of allergies to recombinant humanized antibodies or human mouse chimeric antibodies or any of the components of BL-B01D1\n10. Subjects have a history of autologous or allogeneic stem cell transplantation\n11. Known HIV, active tuberculosis, active Hepatitis B virus infection or active Hepatitis C virus infection\n12. Subjects with active infections requiring systemic treatment\n13. Participated in another clinical trial within 4 weeks prior to participating in the study\n14. Other conditions that the investigator believes that it is not suitable for participating in this clinical trial\n15. Subjects with prolonged QT interval (QTc \\>470 msec), complete left bundle branch block, Grade 3 atrioventricular block\n16. Has received treatment with anthracyclines with a cumulative dose exceeding 360 mg/m2",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Tara Barrineau",
                    "role": "CONTACT",
                    "phone": "4254536841",
                    "email": "tara.barrineau@systimmune.com"
                },
                {
                    "name": "Whitney Eakins",
                    "role": "CONTACT",
                    "email": "whitney.eakins@systimmune.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Clinical Leader",
                    "affiliation": "SystImmune Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "SystImmune Recruiting Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Duarte",
                    "state": "California",
                    "zip": "91010",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.13945,
                        "lon": -117.97729
                    }
                },
                {
                    "facility": "SystImmune Recruiting Site",
                    "status": "RECRUITING",
                    "city": "Orange",
                    "state": "California",
                    "zip": "92868",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.78779,
                        "lon": -117.85311
                    }
                },
                {
                    "facility": "SystImmune Recruiting Site",
                    "status": "RECRUITING",
                    "city": "Boulder",
                    "state": "Colorado",
                    "zip": "80045",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.01499,
                        "lon": -105.27055
                    }
                },
                {
                    "facility": "SystImmune Recruiting Site",
                    "status": "RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33125",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                },
                {
                    "facility": "SystImmune Recruiting Site",
                    "status": "RECRUITING",
                    "city": "Port Saint Lucie",
                    "state": "Florida",
                    "zip": "34952",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 27.29393,
                        "lon": -80.35033
                    }
                },
                {
                    "facility": "SystImmune Recruiting Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Louisville",
                    "state": "Kentucky",
                    "zip": "40202",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.25424,
                        "lon": -85.75941
                    }
                },
                {
                    "facility": "SystImmune Recruiting Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "SystImmune Recruiting Site",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "SystImmune Recruiting Site",
                    "status": "RECRUITING",
                    "city": "Greenville",
                    "state": "South Carolina",
                    "zip": "29605",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.85262,
                        "lon": -82.39401
                    }
                },
                {
                    "facility": "SystImmune Recruiting Site",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "SystImmune Recruiting Site",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75230",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                },
                {
                    "facility": "SystImmune Recruiting Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "SystImmune Recruiting Site",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "SystImmune Recruiting Site",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                },
                {
                    "facility": "SystImmune Recruiting Site",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28040",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "SystImmune Recruiting Site",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28050",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008175",
                    "term": "Lung Neoplasms"
                },
                {
                    "id": "D000002289",
                    "term": "Carcinoma, Non-Small-Cell Lung"
                },
                {
                    "id": "D000055752",
                    "term": "Small Cell Lung Carcinoma"
                },
                {
                    "id": "D000009303",
                    "term": "Nasopharyngeal Neoplasms"
                },
                {
                    "id": "D000077274",
                    "term": "Nasopharyngeal Carcinoma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000012142",
                    "term": "Respiratory Tract Neoplasms"
                },
                {
                    "id": "D000013899",
                    "term": "Thoracic Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                },
                {
                    "id": "D000002283",
                    "term": "Carcinoma, Bronchogenic"
                },
                {
                    "id": "D000001984",
                    "term": "Bronchial Neoplasms"
                },
                {
                    "id": "D000006258",
                    "term": "Head and Neck Neoplasms"
                },
                {
                    "id": "D000010610",
                    "term": "Pharyngeal Neoplasms"
                },
                {
                    "id": "D000010039",
                    "term": "Otorhinolaryngologic Neoplasms"
                },
                {
                    "id": "D000009302",
                    "term": "Nasopharyngeal Diseases"
                },
                {
                    "id": "D000010608",
                    "term": "Pharyngeal Diseases"
                },
                {
                    "id": "D000009057",
                    "term": "Stomatognathic Diseases"
                },
                {
                    "id": "D000010038",
                    "term": "Otorhinolaryngologic Diseases"
                },
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "asFound": "Non-small Cell Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "asFound": "Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M28323",
                    "name": "Small Cell Lung Carcinoma",
                    "asFound": "Small Cell Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1730",
                    "name": "Nasopharyngeal Carcinoma",
                    "asFound": "Nasopharyngeal Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8088",
                    "name": "Esophageal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M12254",
                    "name": "Nasopharyngeal Neoplasms",
                    "asFound": "Nasopharyngeal Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14979",
                    "name": "Respiratory Tract Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16658",
                    "name": "Thoracic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5540",
                    "name": "Carcinoma, Bronchogenic",
                    "relevance": "LOW"
                },
                {
                    "id": "M5260",
                    "name": "Bronchial Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M9348",
                    "name": "Head and Neck Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M13517",
                    "name": "Pharyngeal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M12962",
                    "name": "Otorhinolaryngologic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M12253",
                    "name": "Nasopharyngeal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M13515",
                    "name": "Pharyngeal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12017",
                    "name": "Stomatognathic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12961",
                    "name": "Otorhinolaryngologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "T5271",
                    "name": "Small Cell Lung Cancer",
                    "asFound": "Small Cell Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4047",
                    "name": "Nasopharyngeal Carcinoma",
                    "asFound": "Nasopharyngeal Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T2141",
                    "name": "Esophageal Cancer",
                    "asFound": "Esophageal Cancer",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "BC07",
                    "name": "Mouth and Tooth Diseases"
                },
                {
                    "abbrev": "BC09",
                    "name": "Ear, Nose, and Throat Diseases"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}